InvestorsHub Logo
Followers 185
Posts 2462
Boards Moderated 0
Alias Born 02/10/2017

Re: midastouch017 post# 145

Friday, 01/15/2021 8:27:59 AM

Friday, January 15, 2021 8:27:59 AM

Post# of 238
Thanks just bought another 2k pre market she is going to run hard you can make book on that.

most undervalued gene editing platform AI computational application for green industrial & green agriculture including cannabis, fruits vegetables insects. And Biotech

Biotech subsidiary Biomica
Proof of concept, first-in-man study – Immuno-oncology program.

https://www.biomicamed.com/

EVGN Biomica microbiome-based therapeutics for immunology looks superior to Seres Therapeutics technology 2.5 billion company that went from 2.52-38.00


Seres therapeutics 2.4 billion market cap.
EVGN Biomica 200 million market cap.

EVGN has the superior tech look for a monster move into double digit dollars coming soon.

https://www.evogene.com/



EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.

$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.




$EVGN
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EVGN News